225 related articles for article (PubMed ID: 35797798)
21. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
22. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
[TBL] [Abstract][Full Text] [Related]
23. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
[TBL] [Abstract][Full Text] [Related]
24. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
[TBL] [Abstract][Full Text] [Related]
25. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
[TBL] [Abstract][Full Text] [Related]
26. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
27. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
28. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
[TBL] [Abstract][Full Text] [Related]
29. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology.
Girolami I; Lucenteforte E; Eccher A; Marletta S; Brunelli M; Graziano P; Pisapia P; Malapelle U; Troncone G; Scarpa A; Huang T; Pantanowitz L
Cancer Cytopathol; 2022 Feb; 130(2):96-109. PubMed ID: 34478240
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
32. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
33. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C
J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149
[TBL] [Abstract][Full Text] [Related]
35. Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.
Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y
Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371
[TBL] [Abstract][Full Text] [Related]
36. Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
Minami K; Jimbo N; Tanaka Y; Hokka D; Miyamoto Y; Itoh T; Maniwa Y
Virchows Arch; 2020 Mar; 476(3):469-473. PubMed ID: 31667596
[TBL] [Abstract][Full Text] [Related]
37. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas.
Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B
Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303
[TBL] [Abstract][Full Text] [Related]
38. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
[TBL] [Abstract][Full Text] [Related]
39. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
Chapel DB; Dubuc AM; Hornick JL; Sholl LM
Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
[TBL] [Abstract][Full Text] [Related]
40. Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
Savic I; Myers J
Acta Med Acad; 2021 Apr; 50(1):197-208. PubMed ID: 34075773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
